NCT07224321Phase 2Recruiting

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-03Estimated

Enrollment · participants100Estimated

Source updated2026-08-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-21 · 1 field changed

Primary completion date changed

− Before

~~Nov 2026~~

+ After

Mar 2027

Check registry source

Posted 2026-02-05 · 2 fields changed

Primary completion date changed

− Before

~~Oct 2026~~

+ After

Nov 2026

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Posted 2026-01-16 · 1 field changed

Primary completion date changed

− Before

~~Sep 2026~~

+ After

Oct 2026

Check registry source

Study details

Conditions studied

Type 1 Diabetes Mellitus

Treatments or interventions studied

Technosphere InsulinDrugAlso known as Afrezza
Technosphere InsulinDrugAlso known as Afrezza
Basal insulinDrug

Primary outcomes · main study measures

measure: Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70%; description: Percentage of participants with a CGM-measured TIR 70-180 mg/dL ≥70% during 14 days prior to 13-week visit; timeFrame: 13 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history